[go: up one dir, main page]

NO20053449L - 3-substituerte 4-pyrimidonderivater - Google Patents

3-substituerte 4-pyrimidonderivater

Info

Publication number
NO20053449L
NO20053449L NO20053449A NO20053449A NO20053449L NO 20053449 L NO20053449 L NO 20053449L NO 20053449 A NO20053449 A NO 20053449A NO 20053449 A NO20053449 A NO 20053449A NO 20053449 L NO20053449 L NO 20053449L
Authority
NO
Norway
Prior art keywords
substituted
ring
alkyl group
nitrogen atom
atom
Prior art date
Application number
NO20053449A
Other languages
English (en)
Inventor
Masahiro Okuyama
Yoshihiro Usui
Tokushi Hanano
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20053449L publication Critical patent/NO20053449L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Pyrimidonderivat representert ved formel (I), eller et salt, solvat eller hydrat av dette, som er anvendelig som t-proteinkinase 1-inhibitor: (I) hvor X representerer CH eller nitrogen-atom; R1 representerer en C1-C12-alkyl-gruppe som kan være substituert; R2 representerer en C1-C8-alkylgruppe som kan være substituert, en benzenring som kan være substituert, en naftalenring som kan være substituert, en indanring som kan være substituert, en tetra-hydronaftalenring som kan være substituert eller en eventuelt substituert heterosyklisk ring som har 1-4 hetero-atomer valgt blant oksygenatom, svovel-atom og nitrogenatom, og som har 5-10 ringdannende atomer totalt.
NO20053449A 2002-12-16 2005-07-15 3-substituerte 4-pyrimidonderivater NO20053449L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002383301 2002-12-16
JP2002383300 2002-12-16
PCT/JP2003/015968 WO2004055007A1 (en) 2002-12-16 2003-12-12 3-substituted-4-pyrimidone derivatives

Publications (1)

Publication Number Publication Date
NO20053449L true NO20053449L (no) 2005-07-15

Family

ID=32599307

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053449A NO20053449L (no) 2002-12-16 2005-07-15 3-substituerte 4-pyrimidonderivater

Country Status (13)

Country Link
US (1) US7683069B2 (no)
EP (1) EP1572681B1 (no)
JP (1) JP4616003B2 (no)
KR (1) KR100956052B1 (no)
CN (1) CN1726209B (no)
BR (1) BR0316785A (no)
CA (1) CA2510170C (no)
EA (1) EA009027B1 (no)
MX (1) MXPA05006394A (no)
NO (1) NO20053449L (no)
NZ (1) NZ541074A (no)
WO (1) WO2004055007A1 (no)
ZA (1) ZA200505258B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI241298B (en) 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
AR036604A1 (es) 2001-09-21 2004-09-22 Mitsubishi Pharma Corp Derivados de 4-pirimidona 3-sustituida
KR100881821B1 (ko) 2001-09-21 2009-02-03 미쓰비시 타나베 파마 코퍼레이션 3-치환-4-피리미돈 유도체
TWI357408B (en) 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
AR050865A1 (es) 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
WO2006041404A1 (en) * 2004-10-15 2006-04-20 Astrazeneca Ab Substituted amino-compounds and uses thereof
CN101084198A (zh) * 2004-10-15 2007-12-05 阿斯利康(瑞典)有限公司 取代的氨基-嘧啶酮及其用途
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
ATE530540T1 (de) * 2006-08-23 2011-11-15 Pfizer Prod Inc Pyrimidonverbindungen als gsk-3-inhibitoren
EP1992620A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
EP1992621A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
EP1992625A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Arylamide pyrimidone compounds
EP1992624A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide pyrimidone compounds
EP2464632A1 (en) 2009-08-13 2012-06-20 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives used as tau protein kinase 1 inhibitors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS559099B2 (no) 1972-08-07 1980-03-07
JPS4935633A (no) 1972-08-09 1974-04-02
JPS5124008B2 (no) 1972-08-10 1976-07-21
JPS4935632A (no) 1972-08-10 1974-04-02
JPS5271481A (en) 1975-12-10 1977-06-14 Yoshitomi Pharmaceut Ind Ltd Synthesis of pyridylpyrimidines
JPS52139085A (en) 1976-05-13 1977-11-19 Hokuriku Pharmaceutical 22allylpiperazine derivative and method for its preparation
IN151188B (no) * 1978-02-13 1983-03-05 Smith Kline French Lab
US4507302A (en) * 1979-03-19 1985-03-26 The Upjohn Company Method for treating arthritis with 6-aryl pyrimidine compounds
US4619933A (en) * 1979-09-28 1986-10-28 The Upjohn Company 6-aryl pyrimidines for treating aplastic anemia
US4725600A (en) * 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
EP0354179B1 (de) 1988-07-29 1994-08-17 Ciba-Geigy Ag Thiouracile als Stabilisatoren für chlorhaltige Polymerisate
EP0618968B1 (en) 1991-12-06 1999-10-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
DE4206145A1 (de) * 1992-02-28 1993-09-02 Basf Ag Herbizide n-((pyrimidin-2-yl)aminocarbonyl)benzolfulfonamide
JP3324611B2 (ja) 1992-07-03 2002-09-17 三菱化学株式会社 タウ蛋白質のリン酸化方法
JPH06329551A (ja) 1993-03-22 1994-11-29 Mitsubishi Kasei Corp アルツハイマー病の予防または治療薬およびそのスクリーニング方法
PL313973A1 (en) * 1993-10-12 1996-08-05 Du Pont Merck Pharma 1 n-alkyl-n-arylopyrimidin amines and their derivatives
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
AU733877C (en) 1996-12-05 2003-05-08 Amgen, Inc. Substituted pyrimidine compounds and their use
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
NZ335992A (en) 1996-12-05 2001-09-28 Amgen Inc Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) * 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
AR038955A1 (es) 1996-12-05 2005-02-02 Amgen Inc Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
US6187781B1 (en) * 1997-03-26 2001-02-13 Taisho Pharmaceutical Co., Ltd. 4-Tetrahydropyridylpyrimidine derivatives
TWI241298B (en) * 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
IL150912A0 (en) * 2000-02-25 2003-02-12 Hoffmann La Roche Adenosine receptor modulators
WO2001070728A1 (en) 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-[nitrogen-heterocyclic]pyrimidone derivatives
EP1136482A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
EP1300396B1 (en) * 2000-06-12 2009-01-14 Eisai R&D Management Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
KR100881821B1 (ko) 2001-09-21 2009-02-03 미쓰비시 타나베 파마 코퍼레이션 3-치환-4-피리미돈 유도체
AR036604A1 (es) * 2001-09-21 2004-09-22 Mitsubishi Pharma Corp Derivados de 4-pirimidona 3-sustituida
TWI357408B (en) 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives

Also Published As

Publication number Publication date
JP2006510684A (ja) 2006-03-30
WO2004055007A1 (en) 2004-07-01
KR20050099496A (ko) 2005-10-13
CN1726209A (zh) 2006-01-25
CA2510170C (en) 2011-05-24
AU2003285777A1 (en) 2004-07-09
BR0316785A (pt) 2005-10-25
CN1726209B (zh) 2011-04-13
US7683069B2 (en) 2010-03-23
ZA200505258B (en) 2006-09-27
MXPA05006394A (es) 2007-04-16
JP4616003B2 (ja) 2011-01-19
EA009027B1 (ru) 2007-10-26
CA2510170A1 (en) 2004-07-01
US20070142409A1 (en) 2007-06-21
NZ541074A (en) 2008-04-30
EP1572681B1 (en) 2014-01-22
EA200500984A1 (ru) 2005-12-29
AU2003285777A8 (en) 2004-07-09
KR100956052B1 (ko) 2010-05-06
EP1572681A1 (en) 2005-09-14

Similar Documents

Publication Publication Date Title
EA200400452A1 (ru) Производные 3-замещенных 4-пиримидонов
EA200400453A1 (ru) Производные 3-замещенных 4-пиримидонов
NO20053449L (no) 3-substituerte 4-pyrimidonderivater
NO20073114L (no) Amidforbindelse
MY145140A (en) Amide derivatives, process for preparation thereof and use thereof as insecticide
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
NO20064366L (no) Tiazolderivat
NO20060219L (no) Forbindelser
UA94424C2 (en) 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
NO20061793L (no) 1,4-disubstituerte isoquinilonderlvater som RAF-kinaseinhibitorer nyttige for behandling av proliferative sykdommer
MX2009012283A (es) Derivado heterociclico que contiene nitrogeno que tiene actividad inhibitoria de 11beta-hidroxiesteroide-deshidrogenasa tipo 1.
HRP20070430T3 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
ATE388146T1 (de) 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor
NO20075384L (no) Tiadiazolsubstituerte kumarinderivater og deres anvendelse som leukotrienbiosynteseinhibitorer.
NO20070457L (no) Pyrazolderivater
WO2005003087A3 (en) Oxazole derivatives as antibacterial agents
WO2006123165A3 (en) Pyrimidine derivatives as hsp90 inhibitors
MXPA02011352A (es) Nuevos derivados de benzofurano.
NO20054854L (no) Femrings heterocykliske derivater
TW200517387A (en) Compounds exhibiting thrombopoietin receptor agonism
ATE445619T1 (de) Pyridinylpyrazolopyrimidinon-derivate als pde 7 inhibitoren
DK0753511T3 (da) 4-indol-1-ylsmørsyrederivater, deres fremstilling og deres anvendelse som inhibitorer af alfa 1-adrenerge receptorer og testosteron-5alfa-reduktaser
TW200609218A (en) Bicyclic compounds
NO20070972L (no) Benzyloksyderivater som MAOB-inhibitorer
DK1899331T3 (da) Homomorpholinoxazolidnoner som antibakterielle midler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application